Publications by authors named "Myrthe Veth"

Claim this Profile
P
PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment.
Lisa A King, Myrthe Veth, Marieke Roos, George L Scheffer, Marko A Popovic

J Immunother Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unexpected role of CLASP1 in radiation response and S-phase regulation of head and neck cancer cells.
Reinout H de Roest, Marijke Buijze, Myrthe Veth, Klaas de Lint, Govind Pai

PLoS One· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.
Lisa A King, Myrthe Veth, Victoria Iglesias-Guimarais, Iris Blijdorp, Jan Kloosterman

iScience· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.
Lisa A King, Milon de Jong, Myrthe Veth, David Lutje Hulsik, Parsa Yousefi

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions.
Roeland Lameris, Adam Shahine, Myrthe Veth, Bart Westerman, Dale I Godfrey

J Immunother Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
Lisa A King, Elisa C Toffoli, Myrthe Veth, Victoria Iglesias-Guimarais, Manon C Slot

Cancer Immunol Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Roeland Lameris, Jurjen M Ruben, Victoria Iglesias-Guimarais, Milon de Jong, Myrthe Veth

Cell Rep Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis